China’s National Medical Products Administration has approved AstraZeneca’s (NYSE:AZN) Imfinzi (durvalumab) for the treatment of patients with unresectable Stage 3 (cancer has spread to lymph nodes in the chest) non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

Shares up 1% premarket on light volume.





READ SOURCE

READ  How can the Budget fix slowdown, rural distress and demand deficit?

WHAT YOUR THOUGHTS

Please enter your comment!
Please enter your name here